Lord Abbett & CO. LLC Invests $5.55 Million in uniQure (NASDAQ:QURE)

Lord Abbett & CO. LLC acquired a new position in shares of uniQure (NASDAQ:QURE - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 314,413 shares of the biotechnology company's stock, valued at approximately $5,553,000. Lord Abbett & CO. LLC owned 0.65% of uniQure at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of QURE. Invesco Ltd. boosted its holdings in uniQure by 453.2% in the 4th quarter. Invesco Ltd. now owns 613,601 shares of the biotechnology company's stock valued at $10,836,000 after purchasing an additional 502,684 shares in the last quarter. Sanders Morris Harris LLC boosted its stake in shares of uniQure by 50.0% in the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after buying an additional 34,034 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of uniQure during the 3rd quarter worth $7,360,000. Oppenheimer & Co. Inc. acquired a new position in uniQure during the fourth quarter worth about $320,000. Finally, Palumbo Wealth Management LLC purchased a new position in uniQure in the 4th quarter valued at approximately $437,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on QURE. HC Wainwright reiterated a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Monday, April 21st. StockNews.com upgraded shares of uniQure to a "sell" rating in a report on Tuesday, March 11th. Chardan Capital began coverage on shares of uniQure in a research note on Tuesday, April 1st. They set a "buy" rating and a $38.00 price objective on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Finally, Wells Fargo & Company reduced their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, uniQure currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.80.

uniQure Stock Down 1.5 %

NASDAQ:QURE traded down $0.23 during trading hours on Friday, hitting $14.77. 1,010,082 shares of the company's stock traded hands, compared to its average volume of 1,785,345. The stock's fifty day moving average price is $12.15 and its two-hundred day moving average price is $11.89. The firm has a market cap of $809.04 million, a P/E ratio of -2.98 and a beta of 0.10. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christian Klemt sold 14,341 shares of the business's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. This represents a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 in the last 90 days. Company insiders own 4.74% of the company's stock.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.